COMMENTARY

• Japan's Most Admired Pharma Companies　P. Reed Maurer
  February 20, 2006

• Frustrating Outcome for Industry: Exceptional NHI Price Reduction for Long-listed Drugs
  February 13, 2006

• Requirements for External IRBs to Be Relaxed
  February 13, 2006

• Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
  February 6, 2006

• COMMENTARY 2 articles
  January 30, 2006

• JPLA SEMINAR
  January 30, 2006

• Maurer's Healthcare Insight (72)
  January 30, 2006

• Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
  January 30, 2006

• Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II)　-2-
  January 30, 2006

• Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II)　-1-
  January 30, 2006

• From "Replacement" to "Addition": Prescription Form
  January 23, 2006

• Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I)　－２－
  January 23, 2006

• Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I)　－１－
  January 23, 2006

• A Happy Year 2006 to Japanese Pharmaceutical Stocks!
  January 23, 2006

• Industry Should Insist on Brand Average Market Price Principle
  January 16, 2006

• The Bottom of the Tornado
  January 16, 2006

• ＜New Year's commentary＞Looking at the Pharma Industry Backward from 2009　-1- Sugio Seko, President　Pharma Marketing Survey Research Laboratory　(December, 2005)
  January 9, 2006

• ＜New Year's commentary＞Looking at the Pharma Industry Backward from 2009　-2- Sugio Seko, President　Pharma Marketing Survey Research Laboratory　(December, 2005)
  January 9, 2006

• Schrodinger's Cat
  December 12, 2005

• Top Wholesalers Cut Costs to Offset Declines in Gross Profits
  December 5, 2005

ページ